ZYPREXA INTRAMUSCULAR
Pronunciation: oe-LAN-za-peen (zye-PREX-a)


What it isInjectable second-generation antipsychotic (ZYPREXA INTRAMUSCULAR, 2004) with D2, 5-HT2A, histamine, muscarinic, and alpha-1 blockade; acute agitation.
Why this oneIt controls agitation with less acute dystonia than haloperidol while preserving olanzapine’s sedative effect.
What limits itAvoid close use with parenteral benzodiazepines because cardiorespiratory depression can occur; hypotension and oversedation limit use.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Acute agitation associated with schizophrenia and bipolar I mania | Adults | 10 mg IM (5 or 7.5 mg when clinically warranted) | May repeat up to 10 mg; assess orthostatic hypotension before subsequent doses | 3 doses given 2–4 h apart; total 30 mg/day |
Renal Undefined.
Hepatic Undefined.
Available strengths
Pregnancy No established drug-associated malformation risk; third-trimester exposure risks neonatal extrapyramidal/withdrawal symptoms.
Lactation Present in human milk; monitor infant for sedation, irritability, poor feeding, extrapyramidal symptoms.
| Strength | #/mo | generic $/unit | CostPlus | |
|---|---|---|---|---|
| 10 mg/vial | inj | per unit | $20.92/ea | not offered |
Other forms: Olanzapine (ZYPREXA)
Available combined with: Samidorphan (in LYBALVI) · olanzapine / fluoxetine · olanzapine / samidorphan
⚠ BOXED WARNING
Open Olanzapine IM in the interactive console ↗
